Compass Wealth Management LLC Invests $598,000 in Revvity Inc. $RVTY

Compass Wealth Management LLC purchased a new position in Revvity Inc. (NYSE:RVTY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 5,373 shares of the company’s stock, valued at approximately $598,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Ascentis Independent Advisors purchased a new stake in Revvity during the first quarter worth about $29,000. CYBER HORNET ETFs LLC purchased a new position in Revvity in the second quarter valued at about $32,000. MUFG Securities EMEA plc bought a new position in shares of Revvity during the 2nd quarter valued at approximately $34,000. SJS Investment Consulting Inc. grew its position in shares of Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after acquiring an additional 521 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in shares of Revvity during the 2nd quarter worth approximately $49,000. Institutional investors own 86.65% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on RVTY. Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 30th. Evercore reissued an “outperform” rating on shares of Revvity in a report on Wednesday, August 5th. Wall Street Zen downgraded Revvity from a “buy” rating to a “hold” rating in a research report on Sunday. Stifel Nicolaus lowered their target price on Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research note on Wednesday, May 6th. Finally, Robert W. Baird set a $117.00 price target on Revvity in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, Revvity has a consensus rating of “Hold” and a consensus price target of $108.36.

Revvity Stock Down 1.9%

RVTY opened at $113.99 on Wednesday. The company has a fifty day moving average price of $110.13 and a 200-day moving average price of $100.02. The firm has a market capitalization of $12.72 billion, a P/E ratio of 54.28, a price-to-earnings-growth ratio of 2.13 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. Revvity Inc. has a one year low of $81.22 and a one year high of $118.34.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million for the quarter, compared to the consensus estimate of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm’s revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts expect that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio is currently 13.33%.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.